240 related articles for article (PubMed ID: 19588994)
1. Synthesis and in vivo antitumor efficacy of PEGylated poly(l-lysine) dendrimer-camptothecin conjugates.
Fox ME; Guillaudeu S; Fréchet JM; Jerger K; Macaraeg N; Szoka FC
Mol Pharm; 2009; 6(5):1562-72. PubMed ID: 19588994
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.
Yu D; Peng P; Dharap SS; Wang Y; Mehlig M; Chandna P; Zhao H; Filpula D; Yang K; Borowski V; Borchard G; Zhang Z; Minko T
J Control Release; 2005 Dec; 110(1):90-102. PubMed ID: 16271793
[TBL] [Abstract][Full Text] [Related]
3. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker.
Conover CD; Greenwald RB; Pendri A; Gilbert CW; Shum KL
Cancer Chemother Pharmacol; 1998; 42(5):407-14. PubMed ID: 9771956
[TBL] [Abstract][Full Text] [Related]
4. Influence of dendrimer generation and polyethylene glycol length on the biodistribution of PEGylated dendrimers.
Kojima C; Regino C; Umeda Y; Kobayashi H; Kono K
Int J Pharm; 2010 Jan; 383(1-2):293-6. PubMed ID: 19761822
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of beta-cyclodextrin polymer-camptothecin conjugates.
Cheng J; Khin KT; Davis ME
Mol Pharm; 2004; 1(3):183-93. PubMed ID: 15981921
[TBL] [Abstract][Full Text] [Related]
6. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
7. Capping methotrexate α-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Sberna G; Boyd BJ; Owen DJ; Porter CJ
Mol Pharm; 2011 Apr; 8(2):338-49. PubMed ID: 21171585
[TBL] [Abstract][Full Text] [Related]
8. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
9. Water-soluble poly-(L-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo.
Singer JW; Bhatt R; Tulinsky J; Buhler KR; Heasley E; Klein P; de Vries P
J Control Release; 2001 Jul; 74(1-3):243-7. PubMed ID: 11489501
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
Schluep T; Cheng J; Khin KT; Davis ME
Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
[TBL] [Abstract][Full Text] [Related]
11. Stealth and non-stealth nanocapsules containing camptothecin: in-vitro and in-vivo activity on B16-F10 melanoma.
Loch-Neckel G; Nemen D; Puhl AC; Fernandes D; Stimamiglio MA; Alvarez Silva M; Hangai M; Santos Silva MC; Lemos-Senna E
J Pharm Pharmacol; 2007 Oct; 59(10):1359-64. PubMed ID: 17910810
[TBL] [Abstract][Full Text] [Related]
12. Folate-decorated and reduction-sensitive micelles assembled from amphiphilic polymer-camptothecin conjugates for intracellular drug delivery.
Liu C; Yuan J; Luo X; Chen M; Chen Z; Zhao Y; Li X
Mol Pharm; 2014 Nov; 11(11):4258-69. PubMed ID: 25238329
[TBL] [Abstract][Full Text] [Related]
13. Grafting of poly(ethylene glycol) to poly-lysine augments its lifetime in blood circulation and accumulation in tumors without loss of the ability to associate with siRNA.
Kano A; Moriyama K; Yamano T; Nakamura I; Shimada N; Maruyama A
J Control Release; 2011 Jan; 149(1):2-7. PubMed ID: 20005270
[TBL] [Abstract][Full Text] [Related]
14. Smart AS1411-aptamer conjugated pegylated PAMAM dendrimer for the superior delivery of camptothecin to colon adenocarcinoma in vitro and in vivo.
Alibolandi M; Taghdisi SM; Ramezani P; Hosseini Shamili F; Farzad SA; Abnous K; Ramezani M
Int J Pharm; 2017 Mar; 519(1-2):352-364. PubMed ID: 28126548
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
Matsuzaki T; Takagi A; Furuta T; Ueno S; Kurita A; Nohara G; Kodaira H; Sawada S; Hashimoto S
Oncol Rep; 2012 Jan; 27(1):189-97. PubMed ID: 21935577
[TBL] [Abstract][Full Text] [Related]
16. Development of pH-Sensitive Cationic PEGylated Solid Lipid Nanoparticles for Selective Cancer-Targeted Therapy.
Chuang CH; Wu PC; Tsai TH; Fang YP; Tsai YH; Cheng TC; Huang CC; Huang MY; Chen FM; Hsieh YC; Lin WW; Tsai MJ; Cheng TL
J Biomed Nanotechnol; 2017 Feb; 13(2):192-03. PubMed ID: 29377649
[TBL] [Abstract][Full Text] [Related]
17. The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers.
Kaminskas LM; Boyd BJ; Karellas P; Krippner GY; Lessene R; Kelly B; Porter CJ
Mol Pharm; 2008; 5(3):449-63. PubMed ID: 18393438
[TBL] [Abstract][Full Text] [Related]
18. Polymer-polymer conjugation to fabricate multi-block polymer as novel drug carriers: poly(lactic acid)-poly(ethylene glycol)-poly(L-lysine) to enhance paclitaxel target delivery.
Liu Y; Liu C; Li M; Liu F; Feng L; Zhang L; Zhang N
J Biomed Nanotechnol; 2014 Jun; 10(6):948-58. PubMed ID: 24749390
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and antitumor activity of novel 10-substituted camptothecin analogues.
Li Q; Zu Y; Shi R; Yao L; Fu Y; Yang Z; Li L
Bioorg Med Chem; 2006 Nov; 14(21):7175-82. PubMed ID: 16870453
[TBL] [Abstract][Full Text] [Related]
20. BR2 and CyLoP1 enhance in-vivo SN38 delivery using pegylated PAMAM dendrimers.
Mahmoudi A; Jaafari MR; Ramezanian N; Gholami L; Malaekeh-Nikouei B
Int J Pharm; 2019 Jun; 564():77-89. PubMed ID: 30991135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
